Actinogen Limited
(ASX:ACW) CEO Dr Bill Ketelbey presents at the ASX Investor Series in Sydney.
The biotechnology group’s presentation is titled, “Developing Xanamem™ for Alzheimer’s Dementia”.
Xanamem™ is described as a potential treatment for early and prodromal Alzheimer’s Dementia /mild cognitive impairment which targets the stress hormone cortisol.
Dr Ketelbey discusses why Alzheimer’s disease is emerging as a significant health challenge how there is a huge and growing global market seeking treatment.
The presentation details the company’s lead drug candidate Xanamem™ including its development milestones, clinical advisory board and pipeline.
Dr Ketelbey advises Final Phase I and preclinical results due mid-2015, and funded through to completion of these studies, while IND filing and Phase II study is planned for 2016.
